In the early stage, clinical trial subject recruitment mainly relied on manual screening and offline channels, which suffered from low efficiency and poor matching accuracy. Many projects were frequently delayed due to insufficient enrollment. With the boom of pharmaceutical innovation in China, the industry has seen a growing demand for compliant and efficient recruitment services. While some enterprises adopted information-based management, the sector still grapples with prominent pain points such as information asymmetry and limited patient awareness.
Against this backdrop, Deepwise leverages medical big data and AI technologies to independently develop an intelligent matching platform. It adopts a model of "algorithm-based preliminary screening plus manual review" to realize precise matching, greatly shortening the recruitment cycle. Meanwhile, we have built a full-process compliance management system that strictly complies with GCP and personal information protection regulations, driving the industry to evolve from extensive management to standardized operation.
To date, we have established in-depth partnerships with numerous Grade A tertiary hospitals and innovative pharmaceutical companies, creating a win-win ecosystem connecting pharmaceutical enterprises, hospitals and patients. We are striving to bridge the final gap for pharmaceutical innovation.
分享文章